President, Astellas Pharma US
Mark Reisenauer is President, Astellas Pharma US. In this role, he is responsible for the operations of Astellas Pharma across the U.S., a $4 billion affiliate of the Tokyo-based pharmaceutical company headquartered in Northbrook, Ill. with 1,200 employees. Astellas is a company dedicated to improving the health of people around the world through the provision of innovative pharmaceutical products.
Reisenauer was most recently Senior Vice President of Astellas’ Oncology business unit and joined Astellas in 2011 as Vice President of Oncology Sales and Marketing. During his tenure, Mark’s leadership has yielded the fastest-growing franchise in Astellas’ US portfolio, as Oncology franchise sales grew from less than 10 percent of sales to approximately 50 percent of US sales. He has been instrumental in bringing many new important oncology treatments to patients, including XTANDI® (enzalutamide), XOSPATA® (gilteritinib) and PADCEV™ (enfortumab vedotin-ejfv). All three products have become standards of care in their approved indications.
Prior to joining Astellas, Reisenauer served as Senior Vice President and Chief Commercial Officer of Micromet Inc. (now part of Amgen), where he led investor and public relations, new product planning, and commercial launch planning. Previously, Reisenauer held various sales and marketing leadership roles at AstraZeneca, Bristol Myers Squibb, Pharmacia, and Abbott. Reisenauer earned a bachelor’s degree in political science from the University of Wisconsin.
Reisenauer serves on the board of the Pharmaceutical Research and Manufacturers of America (PhRMA), an organization dedicated to advancing policies that ensure continued investment in biopharmaceutical innovation.
